The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment?
作者信息
Dauby Nicolas, Bottieau Emmanuel
机构信息
Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium; Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Belgium; Environmental Health Research Centre, Public Health School, ULB, Brussels, Belgium.
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
出版信息
Int J Infect Dis. 2021 Feb;103:1-2. doi: 10.1016/j.ijid.2020.10.032. Epub 2020 Oct 17.
Abstract
摘要
相似文献
1
The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment?羟氯喹在新冠病毒肺炎中未完成的故事：在正确的时机使用正确的抗炎剂量？
Int J Infect Dis. 2021 Feb;103:1-2. doi: 10.1016/j.ijid.2020.10.032. Epub 2020 Oct 17.
2
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.羟氯喹预防 COVID-19 的集群随机试验。
N Engl J Med. 2021 Feb 4;384(5):417-427. doi: 10.1056/NEJMoa2021801. Epub 2020 Nov 24.
3
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.启动羟氯喹治疗 COVID-19 感染负荷剂量的理由——DisCoVeRy 试验。
J Antimicrob Chemother. 2020 Sep 1;75(9):2376-2380. doi: 10.1093/jac/dkaa191.
4
Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.阿奇霉素联合羟氯喹治疗因 2019 冠状病毒病（COVID-19）入住重症监护病房的患者：随机对照试验 AZIQUINE-ICU 的方案。
Trials. 2020 Jul 8;21(1):631. doi: 10.1186/s13063-020-04566-x.
5
[Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic].[羟氯喹啉。冠状病毒大流行时期心脏病学的观点]
Medicina (B Aires). 2020;80(3):271-274.
6
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?羟氯喹作为 COVID-19 的预防或治疗药物：证据说了什么？
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
7
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.羟氯喹能保护风湿病患者免受新型冠状病毒肺炎（COVID-19）感染吗？对Heldwein和Calado所著的《羟氯喹能预防新型冠状病毒肺炎（COVID-19）传播吗？》以及Joob和Wiwanitkit所著的《系统性红斑狼疮、羟氯喹与非系统性红斑狼疮的新型冠状病毒肺炎（COVID-19）患者：一则评论》的回应
Ann Rheum Dis. 2020 Jun;79(6):e62. doi: 10.1136/annrheumdis-2020-217524. Epub 2020 Apr 23.
8
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.羟氯喹/氯喹治疗 COVID-19 的影响：一枚硬币的两面。
J Interferon Cytokine Res. 2020 Oct;40(10):469-471. doi: 10.1089/jir.2020.0105. Epub 2020 Sep 1.
9
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020.2020 年法国长期接受羟氯喹治疗的类肉瘤病患者中的 COVID-19 病例。
Emerg Infect Dis. 2020 Oct;26(10):2513-2515. doi: 10.3201/eid2610.201816. Epub 2020 Jul 1.
10
Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.COVID-19 住院患者中阿奇霉素和羟氯喹的主动预防（ProPAC-COVID）：统计分析计划。
Trials. 2020 Oct 20;21(1):867. doi: 10.1186/s13063-020-04795-0.
引用本文的文献
1
Drugs for COVID-19 Treatment: A New Challenge.新冠病毒治疗药物：新的挑战。
Appl Biochem Biotechnol. 2023 Jun;195(6):3653-3670. doi: 10.1007/s12010-023-04439-4. Epub 2023 Mar 24.
2
Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19.雾化吸入等渗羟氯喹气雾剂用于COVID-19的潜在治疗
Pharmaceutics. 2021 Aug 14;13(8):1260. doi: 10.3390/pharmaceutics13081260.
3
In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.体外评估酮替芬、吲哚美辛和萘普生单独及联合应用对 SARS-CoV-2 的抗病毒活性。
Viruses. 2021 Mar 26;13(4):558. doi: 10.3390/v13040558.
4
Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.羟氯喹对 TLR 信号的影响：在 COVID-19 中被低估但不容忽视。
J Immunol Res. 2021 Mar 9;2021:6659410. doi: 10.1155/2021/6659410. eCollection 2021.
5
Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH).治疗 HIV 感染者（PLWH）COVID-19 的药物治疗考虑因素。
Expert Opin Pharmacother. 2021 Jun;22(9):1127-1141. doi: 10.1080/14656566.2021.1887140. Epub 2021 Feb 26.
6
Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'".对《观察性研究中羟氯喹的感知疗效：“治疗目标”的混杂效应结果》的回复
Int J Antimicrob Agents. 2021 Apr;57(4):106307. doi: 10.1016/j.ijantimicag.2021.106307. Epub 2021 Feb 17.
7
Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?新冠疫情后时代的羟氯喹：这场大流行会颠覆数十年的临床实践吗？
Clin Rheumatol. 2021 Apr;40(4):1649-1657. doi: 10.1007/s10067-020-05572-9. Epub 2021 Jan 15.
8
Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'.对《低剂量羟氯喹治疗与COVID-19住院患者较低死亡率：关联并不意味着因果关系》的回复
Int J Antimicrob Agents. 2021 Feb;57(2):106261. doi: 10.1016/j.ijantimicag.2020.106261. Epub 2020 Dec 13.
9
Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial.机器学习是识别可能从羟氯喹治疗中获益的新冠肺炎患者的更好方法吗？——识别试验
J Clin Med. 2020 Nov 26;9(12):3834. doi: 10.3390/jcm9123834.
10
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020.2020 年 3 月至 6 月，法国马赛长期护理机构中依赖他人生活的老年居民中感染 SARS-CoV-2 的模式。
Int J Antimicrob Agents. 2020 Dec;56(6):106219. doi: 10.1016/j.ijantimicag.2020.106219. Epub 2020 Nov 13.
Zotero 插件